FINWIRES · TerminalLIVE
FINWIRES

Posco Holdings to Sell Stake in POSCO DX for KRW 482 Billion

By

Posco Holdings (KRX:005490) has decided to dispose of 23.4 million common shares of its affiliate POSCO DX, valued at approximately 481.7 won, with the block trade scheduled for Sept. 7.

The divestment, representing 0.77% of the company's consolidated equity, aims to reduce the holding company discount and secure strategic investment capital, according to a bourse filing on Friday.

Alongside the share sale, Posco Holdings will enter a three-year Price Return Swap contract based on a reference price of 20,600 won per share, with settlement tied to the actual disposal value.

Post-transaction, Posco Holdings will retain a 50.0% stake in POSCO DX, maintaining control over the IT services and engineering subsidiary.

Related Articles

Asia

Aspial Lifestyle's H1 Attributable Profit Surges 88%

Aspial Lifestyle's (SGX:5UF) recorded an 88% rise in attributable profit in the first half of 2026 to SG$52.4 million from SG$27.9 million a year prior.Earnings per share stood at SG$0.0277, up from SG$0.015 previously, according to a Friday filing with the Singapore bourse.Revenue jumped 26% to SG$464.2 million from SG$367.2 million in the year-ago period.

SGX:5UF
Asia

Sino Biopharma Unit Gets China Nod to Market Lung Cancer Drug

Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group's Benmelstobart Injection obtained marketing approval from China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The approval is for use of the drug in combination with chemotherapy and sequentially followed by Anlotinib Hydrochloride Capsules for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer.

HKG:1177
Asia

Lygend Resources Gets CSRC Nod for China Listed-Share IPO

Lygend Resources & Technology (HKG:2245) obtained approval for its registration application related to its China listed-share initial public offering from the China Securities Regulatory Commission (CSRC).The share offering is subject to various conditions, including certain final regulatory approvals, according to a Friday Hong Kong bourse filing.

HKG:2245